Solid-Phase Peptide Synthesis (SPPS): How Peptides Are Made
How research peptides are made: Fmoc solid-phase peptide synthesis (SPPS) from resin loading through cleavage to HPLC purification, explained step by step.
Solid-phase peptide synthesis (SPPS) is the chemical methodology by which virtually all research-grade peptides are manufactured. The technique was developed by Robert Bruce Merrifield at Rockefeller University, whose 1963 paper in the Journal of the American Chemical Society described the first successful anchoring of an amino acid to a solid resin support and iterative chain elongation to synthesise a tetrapeptide. The elegance of Merrifield's approach — working from a solid support rather than in solution, which eliminates the need to isolate intermediates — transformed peptide chemistry from a labour-intensive art into a systematic, automatable process. Merrifield was awarded the Nobel Prize in Chemistry in 1984 for this work.
Fmoc vs Boc chemistry
Modern SPPS employs one of two principal protecting group strategies for the alpha-amino group of each amino acid monomer: 9-fluorenylmethoxycarbonyl (Fmoc) or tert-butyloxycarbonyl (Boc). Boc chemistry, the original Merrifield approach, uses trifluoroacetic acid (TFA) for iterative Boc deprotection and requires hydrogen fluoride (HF) for the final cleavage from resin — a hazardous reagent requiring specialist equipment. The Fmoc protecting group was introduced by Carpino and Han in 1970, and its application to solid-phase synthesis was developed over the following years; Fmoc uses a mild base (typically 20% piperidine in DMF) for Nα deprotection and TFA-containing cocktails for cleavage, making it more widely accessible and compatible with automated synthesiser platforms. As Amblard and colleagues note in their 2006 protocols review, the Fmoc/tBu approach is now the most commonly used methodology for peptide production, and the vast majority of research peptides made commercially today are manufactured this way.
Resin loading and chain elongation
SPPS proceeds from the C-terminus to the N-terminus. The first amino acid (C-terminal residue of the target sequence) is attached via its carboxyl group to the solid resin support through a linker — commonly a Wang linker (for C-terminal acid products) or a Rink amide linker (for C-terminal amide products). This covalent attachment is termed resin loading, quantified as millimoles of amino acid per gram of resin (mmol/g). After loading, each subsequent amino acid in the sequence is coupled stepwise: the Fmoc group on the resin-bound chain is removed by piperidine treatment; the incoming Fmoc-amino acid is activated at its carboxyl group using a coupling reagent (e.g. HATU, HBTU, or DIC/Oxyma); and the activated carboxyl group reacts with the free amine to form a new peptide bond. This deprotection–coupling cycle is repeated for each residue in the target sequence.
Cleavage and global deprotection
Once the full sequence has been assembled on the resin, a cleavage cocktail — typically a mixture of TFA with scavengers such as water, triisopropylsilane (TIPS), and dithiothreitol (DTT) or ethane dithiol (EDT) for cysteine-containing sequences — simultaneously cleaves the peptide from the resin linker and removes the acid-labile side-chain protecting groups (Trt, Pbf, Boc, tBu) in a single step. The crude peptide precipitates into cold diethyl ether and is isolated by filtration or centrifugation. At this stage, the crude peptide typically contains the target sequence plus a mixture of truncated sequences (failure sequences from incomplete coupling steps), deletion sequences, and side-chain modification by-products.
HPLC purification: from crude to research-grade
Crude peptide straight off the resin is a mixture: the target sequence alongside truncation, deletion and side-product impurities. Its purity is strongly sequence-dependent — some sequences come off relatively clean, others far from it — but crude material routinely falls well short of what rigorous in-vitro research needs, which is why a purification step is not optional. Preparative reversed-phase HPLC (prep-RP-HPLC) is the standard method, and as Mant and colleagues document, RP-HPLC has been the workhorse for peptide isolation and purification for decades. In practice this typically means a C18 stationary phase with an acetonitrile/water gradient containing TFA as an ion-pairing modifier, run to resolve the target peptide from its nearest-eluting impurities. Fractions meeting the target purity by analytical HPLC are pooled and lyophilised to give the final research-grade powder. There is no universal regulatory purity threshold — how pure is pure enough depends on the application — but crude or partially purified peptide is not appropriate for controlled mechanistic studies, and a defined, documented purity figure is what separates research-grade material from the rest. If you want to understand how that purity figure is measured, see our guide to reading an HPLC purity report .
Why USA manufacturing matters
Regulatory environment: US peptide manufacturers operating in a GMP-aligned environment are subject to FDA oversight, which provides structural accountability absent from unregulated grey-market operations Quality management systems: established US synthesis facilities maintain documented SOPs for raw material qualification, in-process controls, and final product release testing Independent verification: US-manufactured peptides can be and are independently verified by accredited US analytical laboratories, providing a traceable quality chain from synthesis through testing to supply Counterfeit risk: unregulated grey-market synthesis operations that sell without an independent, batch-specific Certificate of Analysis have been documented as a primary source of mislabelled, underdosed, and contaminated research material Vivera Labs sources exclusively from USA manufacturers and provides independent third-party COAs for every batch Understanding the SPPS manufacturing process equips researchers to evaluate supplier quality claims with appropriate scepticism. A supplier unable to specify their manufacturing origin, provide a chain-of-custody from synthesis to testing, or supply a batch-specific COA from an independent accredited laboratory cannot demonstrate the compound integrity that reproducible in-vitro research requires. All Vivera Labs peptides are USA-manufactured and supplied for in-vitro laboratory research use only.
Frequently Asked Questions What is solid-phase peptide synthesis (SPPS)? SPPS is the chemical methodology by which virtually all research-grade peptides are manufactured. It was developed by Robert Bruce Merrifield at Rockefeller University, whose 1963 paper described anchoring an amino acid to a solid resin support and iteratively elongating the chain, work for which he was awarded the Nobel Prize in Chemistry in 1984.
What is the difference between Fmoc and Boc chemistry? Boc chemistry, the original Merrifield approach, uses trifluoroacetic acid for iterative deprotection and requires hazardous hydrogen fluoride for final cleavage. Fmoc chemistry, introduced by Carpino and Han in 1970, uses a mild base such as 20% piperidine in DMF for deprotection and TFA-containing cocktails for cleavage, making it more accessible and compatible with automated synthesisers, and it is now the most commonly used methodology.
How does chain elongation work in SPPS? SPPS proceeds from the C-terminus to the N-terminus. The first amino acid is attached to the resin via a linker in a step called resin loading, then each subsequent residue is coupled by removing the Fmoc group with piperidine, activating the incoming Fmoc-amino acid with a coupling reagent, and forming a new peptide bond. This deprotection–coupling cycle repeats for every residue in the sequence.
Why is crude peptide purified by HPLC? Crude peptide straight off the resin is a mixture of the target sequence alongside truncation, deletion and side-product impurities, and it routinely falls short of what rigorous in-vitro research needs. Preparative reversed-phase HPLC is the standard purification method, typically a C18 phase with an acetonitrile/water gradient containing TFA, with fractions meeting the target purity pooled and lyophilised into the final research-grade powder. You can see how that purity figure is measured in our guide to reading an HPLC purity report .
Related
Continue reading
For in-vitro laboratory research use only. Not for human or veterinary use, consumption, or therapeutic application. No medical claims are made.
